|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
41,504,000 |
Market
Cap: |
1.35(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$21.06 - $40.91 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 625 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
137,001 |
244,681 |
382,081 |
1,004,450 |
Total Sell Value |
$4,598,859 |
$7,967,692 |
$11,068,318 |
$25,236,488 |
Total People Sold |
2 |
4 |
5 |
7 |
Total Sell Transactions |
3 |
10 |
15 |
42 |
End Date |
2024-03-01 |
2023-11-29 |
2023-05-31 |
2022-05-31 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Longitude Venture Partners L.p. |
10% Owner |
|
2017-12-08 |
4 |
S |
$17.34 |
$17,340,000 |
I/I |
(1,000,000) |
45,620 |
|
- |
|
Hirsch David |
Director |
|
2017-12-08 |
4 |
S |
$17.34 |
$17,340,000 |
I/I |
(1,000,000) |
45,620 |
|
- |
|
Skyline Venture Management V, Llc |
10% Owner |
|
2017-12-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(800,000) |
2,149,916 |
|
- |
|
Kaneko Yasunori |
10% Owner |
|
2017-12-05 |
4 |
A |
$0.00 |
$0 |
I/I |
270 |
270 |
|
- |
|
Kaneko Yasunori |
10% Owner |
|
2017-12-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(800,000) |
2,149,916 |
|
- |
|
Freund John Gordon |
Director |
|
2017-12-05 |
4 |
A |
$0.00 |
$0 |
I/I |
11,715 |
11,715 |
|
- |
|
Freund John Gordon |
Director |
|
2017-12-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(800,000) |
2,149,916 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2017-11-21 |
4 |
AS |
$19.00 |
$10,868 |
D/D |
(572) |
25,723 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2017-11-21 |
4 |
OE |
$0.28 |
$160 |
D/D |
572 |
26,295 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2017-11-17 |
4 |
AS |
$17.00 |
$68,493 |
D/D |
(4,029) |
25,723 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2017-11-17 |
4 |
OE |
$0.28 |
$893 |
D/D |
3,189 |
27,802 |
|
- |
|
Heffernan Michael Thomas |
Chairman, President and CEO |
|
2017-11-15 |
4 |
AS |
$15.53 |
$776,500 |
D/D |
(50,000) |
558,987 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2017-10-25 |
4 |
OE |
$3.38 |
$6,121 |
D/D |
1,811 |
26,563 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2017-08-04 |
4 |
D |
$12.39 |
$2,478 |
D/D |
(200) |
110,803 |
|
- |
|
Heffernan Michael Thomas |
Chairman, President and CEO |
|
2017-08-04 |
4 |
D |
$12.39 |
$9,119 |
D/D |
(736) |
608,987 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2017-08-04 |
4 |
D |
$12.39 |
$2,478 |
D/D |
(200) |
24,752 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2017-07-28 |
4 |
A |
$10.60 |
$8,226 |
D/D |
776 |
111,003 |
|
- |
|
Heffernan Michael Thomas |
Chairman, President and CEO |
|
2017-07-28 |
4 |
A |
$10.60 |
$6,784 |
D/D |
640 |
609,723 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2017-07-28 |
4 |
A |
$10.60 |
$6,773 |
D/D |
639 |
24,952 |
|
- |
|
Ciaffoni Joseph |
Chief Operating Officer |
|
2017-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
84,268 |
84,268 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2017-05-12 |
4 |
B |
$9.18 |
$91,800 |
D/D |
10,000 |
110,227 |
2.74 |
- |
|
Heffernan Michael Thomas |
Chairman, President and CEO |
|
2017-03-17 |
4 |
D |
$14.95 |
$22,006 |
D/D |
(1,472) |
609,083 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2017-03-17 |
4 |
D |
$14.95 |
$5,801 |
D/D |
(388) |
100,227 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2017-03-17 |
4 |
D |
$14.95 |
$5,801 |
D/D |
(388) |
24,313 |
|
- |
|
Duke Barry S |
See remarks |
|
2017-03-17 |
4 |
D |
$14.95 |
$5,801 |
D/D |
(388) |
20,087 |
|
- |
|
391 Records found
|
|
Page 14 of 16 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|